Erythrocyte concentrate, CMV negative

Code 'Blood Service'

Cfr original product sheet

NIHDI Code

Hospitalized: 752 463

Non-hospitalized: 752 452

One of the aims of introducing generalized deleukocytering for labile blood products was to prevent the transmission of cytomegalovirus by transfusion.

White blood cell removal is generally considered a valid if not equivalent alternative to the selection of blood products from CMV-seronegative donors. Deleted blood products are accepted as CMV-safe for most indications. CMV-negative products were removed from the list of legally approved blood products for which specific reimbursement is provided (MB of December 21, 2004).

Based on domestic and foreign expert opinions, two indications have been retained where dual CMV protection, i.e., deleukocyter and CMV seronegative donor status, is still considered desirable:

• Intrauterine transfusion
• Transfusie bij neonaten <1500g

For these applications, CMV-negative erythrocyte concentrates can be obtained from Blood Service .

The erythrocyte concentrate for intrauterine transfusion is described separately.

The label of these products bears the statement "CMV negative" in the lower right quadrant, in accordance with the legal provisions. General characteristics, additional operations, product code and nomenclature number of these products do not otherwise differ from the corresponding products without known CMV status.

By medical prescription, after order.